The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
Open accessAbstract
The farnesoid X receptor (FXR) is a bile acid activated nuclear receptor. Zucker (fa/fa) rats, harboring a loss of function mutation of the leptin receptor, develop diabetes, insulin resistance, obesity, and liver steatosis. In this study, we investigated the effect of FXR activation by 6-ethyl-chenodeoxycholic acid, (6E-CDCA, 10 mg/kg) on insulin resistance and liver and muscle lipid metabolism in fa/fa rats and compared its activity with rosiglitazone (10 mg/kg) alone or in combination with 6E-CDCA (5 mg/kg each). In comparison to lean (fa/+), fa/fa rats on a normal diet developed insulin resistance and liver steatosis. FXR activation protected against body weight gain and liver and muscle fat deposition and reversed insulin resistance as assessed by insulin responsive substrate-1 phosphorylation on serine 312 in liver and muscles. Activation of FXR reduced liver expression of genes involved in fatty acid synthesis, lipogenesis, and gluconeogenesis. In the muscles, FXR treatment reduced free fatty acid synthesis. Rosiglitazone reduced blood insulin, glucose, triglyceride, free fatty acid, and cholesterol plasma levels but promoted body weight gain (20%) and liver fat deposition. FXR activation reduced high density lipoprotein plasma levels. In summary, FXR administration reversed insulin resistance and correct lipid metabolism abnormalities in an obesity animal model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Bile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Tumor necrosis factor alpha inhibits signaling from the insulin receptor.
Hotamisligil, G. S., Murray, D. L., Choy, L. N., & Spiegelman, B. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4854 · Cited by 1,199
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953
Farnesoid X receptor is essential for normal glucose homeostasis
Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 882
The role of TNFα and TNF receptors in obesity and insulin resistance
Hotamisligil, G. S. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00490.x · Cited by 780
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Cariou, B., van Harmelen, K., Duran-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J.-C., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 552
A Molecular Basis for Insulin Resistance
Paz, K., Hemi, R., LeRoith, D., Karasik, A., Elhanany, E., Kanety, H., & Zick, Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29911 · Cited by 549
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Sharma, A. M., & Staels, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1268 · Cited by 479
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
Self-citationTumor Necrosis Factor α-induced Phosphorylation of Insulin Receptor Substrate-1 (IRS-1)
Kanety, H., Feinstein, R., Papa, M. Z., Hemi, R., & Karasik, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23780 · Cited by 434
Retinoid X Receptor Heterodimers in the Metabolic Syndrome
Shulman, A. I., & Mangelsdorf, D. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043590 · Cited by 380
Zhang, Y., Castellani, L. W., Sinal, C. J., Gonzalez, F. J., & Edwards, P. A. (2004) · Genes & Development · doi:10.1101/gad.1138104 · Cited by 368
Treatment of non-alcoholic fatty liver disease
Adams, L. A., & Angulo, P. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042200 · Cited by 346
Animal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337
Prevention of cholesterol gallstone disease by FXR agonists in a mouse model
Moschetta, A., Bookout, A. L., & Mangelsdorf, D. J. (2004) · Nature Medicine · doi:10.1038/nm1138 · Cited by 325
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Insulin resistance: a phosphorylation-based uncoupling of insulin signaling
Zick, Y. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02129-8 · Cited by 292
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14505 · Cited by 286
Claudel, T., Sturm, E., Duez, H., Torra, I. P., Sirvent, A., Kosykh, V., Fruchart, J.-C., Dallongeville, J., Hum, D. W., Kuipers, F., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214505 · Cited by 279
Duran-Sandoval, D., Cariou, B., Percevault, F., Hennuyer, N., Grefhorst, A., van Dijk, T. H., Gonzalez, F. J., Fruchart, J.-C., Kuipers, F., & Staels, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501931200 · Cited by 239
Kupffer cells mediate leptin-induced liver fibrosis
Wang, J., Leclercq, I., Brymora, J. M., Xu, N., Ramezani–Moghadam, M., London, R. M., Brigstock, D., & George, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.011 · Cited by 210
Targeting farnesoid X receptor for liver and metabolic disorders
Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E., & Santucci, L. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.06.001 · Cited by 196
Self-citationFiorucci, S., Clerici, C., Antonelli, E., Orlandi, S., Goodwin, B., Sadeghpour, B. M., Sabatino, G., Russo, G., Castellani, D., Willson, T. M., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079665 · Cited by 196
Self-citationRizzo, G., Sante, M. D., Mencarelli, A., Renga, B., Gioiello, A., Pellicciari, R., & Fiorucci, S. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023820 · Cited by 161
Self-citationEffects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice†
García‐Ruíz, I., Rodríguez‐Juan, C., Díaz-Sanjuán, T., Martínez, M. Á., Muñoz‐Yagüe, T., & Solis-Herruzo, J. A. (2007) · Hepatology · doi:10.1002/hep.21687 · Cited by 127
Non-alcoholic steatohepatitis and animal models: Understanding the human disease
Varela‐Rey, M., Embade, N., Ariz, U., Lu, S. C.-L., Mato, J. M., & Martínez‐Chantar, M. L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.10.027 · Cited by 121
Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor
Savkur, R. S., Bramlett, K. S., Michael, L. F., & Burris, T. P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.141 · Cited by 96
George, J., & Liddle, C. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 91
Cho, N., & Momose, Y. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608786413474 · Cited by 81
Development of insulin resistance and hyperphagia in Zucker fatty rats
Durham, H. A., & Truett, G. E. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00428.2004 · Cited by 68
Farnesoid X Receptor Induces GLUT4 Expression Through FXR Response Element in the GLUT4 Promoter
Shen, H., Zhang, Y., Ding, H., Wang, X., Chen, L., Jiang, H., & Shen, X. (2008) · Cellular Physiology and Biochemistry · doi:10.1159/000149779 · Cited by 66
Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Fiorucci, S., Mencarelli, A., Distrutti, E., et al. (2009) · Current Medicinal Chemistry · doi:10.2174/092986710790112666 · Cited by 61
Self-citationThe farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
Cariou, B. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74605-6 · Cited by 59
Farnesoid X receptor agonists in biliary tract disease
Fiorucci, S., & Baldelli, F. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328324f87e · Cited by 56
Self-citation
Cited by
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Metadata
- Authors
- Cipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 51
- Issue
- 4
- Pages
- 771-784
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2111160264
- Cited by
- 416
- References
- 41
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.